方红明--肿瘤个体化靶向治疗的现状与进展__培训课件.pptVIP

* * 临床研究发现，EGFR表达量高的非小细胞肺癌患者接受易瑞沙治疗，无进展生存率明显高于EGFR表达量低的患者 * * EGFR E18/19/21突变接受吉非替尼治疗获益显著 * 而， EGFR E20突变患者对吉非替尼治疗，表现为要耐药 * * * * * * * * * * CRC, colorectal cancer * EGFR, epidermal growth factor receptor. The BOND study showed no correlation between EGFR receptor status and clinical response, as determined by immunohistochemistry. For instance, the data showed that patients given irinotecan plus cetuximab had a consistent response rate of 20% to 25%, regardless of whether they had a low or high percentage of EGFR-expressing cells or a low or strong EGFR staining intensity. In other wo